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Abstract 
Background: Evidence from clinical and pathological studies suggests a role for both α-synuclein 
and amyloid-β in the pathophysiology of dementia associated with PD.  Recent work demonstrated 
improvement in memory and reduced amyloid-β burden in transgenic murine Alzheimer models given 
subcutaneous apomorphine.   
Objective: To determine whether ante-mortem exposure to apomorphine was associated with lower 
levels of amyloid-β in brain tissue in a clinicopathological study of PD.   
Methods: The case notes of donors with pathologically proven PD who had (n=36) and had not 
received apomorphine (n=35) during life for motor complications were reviewed to determine 
presence or absence of cognitive impairment.  The four groups were well matched for disease 
duration, age at death, gender and apolipoprotein E4 genotype.  The severity of amyloid-β 
mature/diffuse plaque load, tau pathology and α-synuclein pathology were all established.  Cerebral 
amyloid angiopathy was determined based on a 4-tier grading system. 
Results: Within the cognitively normal cases, significantly reduced amyloid-β deposition was present 
in those with ante-mortem apomorphine exposure; this finding was not replicated in those with 
cognitive impairment plus previous apomorphine use.  In the apomorphine cognitively normal group 
only, a significant negative association was observed between maximum apomorphine dose received 
and amyloid-β burden.  Early and maximum doses of apomorphine plus apolipoprotein genotype and 
gender were significant predictors of total plaque load in an explanatory model.   
Conclusion: This exploratory study suggests that apomorphine may have a modifying effect on 
amyloid deposition in non-demented PD cases and thus may represent a potential therapy to reduce 
cognitive impairment in PD. 
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Introduction 
Dementia occurs in up to 80% of Parkinson’s disease (PD) subjects when followed longitudinally.1-3  
Current treatments for PD dementia (PDD) may improve cognitive and behavioural symptoms,4 but 
have no effect on disease progression. 
The pathophysiology of PDD is poorly understood and may vary between individuals, but evidence 
from clinical5 and pathological studies6-11 indicate that amyloid-β (Aβ), neurofibrillary tangle 
pathology and cortical Lewy body (LB) deposition are significant factors.  Furthermore, a synergistic 
interaction between α-synuclein and Aβ accumulation has been found both in vitro 6, 7, 12 and in 
transgenic mice models,13, 14 with concurrent evidence that  Aβ promotes α-synuclein fibrillization and 
thus may influence the progression of cognitive decline.14  
A therapy that prevents Aβ aggregation could conceivably be effective in the prevention or delay of 
Aβ-associated neurotoxicity.  A new class of small molecules, structurally related to apomorphine, 
prevent Aβ fibril formation in vivo and undergo rapid autoxidation, suggesting that these autoxidation 
products may inhibit Aβ fibrillization.15  More recently, transgenic Alzheimer disease (AD) mouse 
models treated with apomorphine demonstrated improvements in short-term memory function and 
significant reductions in intraneuronal Aβ accumulation, possibly due to antioxidative stress 
mechanisms.16 
Given the role of Aβ aggregation in the etiology of PDD and the use of apomorphine in the 
management of motor complications in PD, we sought to determine whether apomorphine may have 
anti-amyloid effects in a clinicopathological study.  We hypothesized that non-demented PD subjects 
who had received apomorphine ante-mortem would have reduced Aβ burden compared to a matched 
group who had not received this treatment. 
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Materials and Methods 
Case selection 
Forty three PD cases with exposure to apomorphine in life (Apo+) diagnosed using accepted 
neuropathological criteria17 were identified from donors to Queen Square Brain Bank for Neurological 
Disorders, University College London.  Apomorphine naïve cases (Apo-, n=38) were matched to age 
at disease onset, disease duration and age at death.  Presence or absence of dementia was determined 
retrospectively by review of case notes and agreed by consensus of movement disorder specialists 
(A.J.Y, H.L., D.J.B.), according to established criteria.18  Specifically, cognitive deficits severe 
enough to impact on activities of daily living, with a neuropsychological assessment (if available) was 
considered a positive history for PDD.18  Other data collected included dose (early (within one month 
of commencement), one year, maximum dose), duration and method of delivery of apomorphine 
therapy; anticholinergic drug exposure (a potential confounder19); dopaminergic medication use; and 
clinical and demographic data.  Lifetime cumulative levodopa dose was calculated using a previously 
described method.20  An approximation for cumulative apomorphine dose was calculated using the 
following equation, approximating to the area under the curve: ((early apomorphine dose (mg) + one 
year dose)/2*1 + (one year + maximum apomorphine dose)/2*(duration of apomorphine use (years)-
1))*365.25.  All study subjects provided written informed consent ante-mortem.  Cases were collected 
using a protocol approved by London Multicentre Research Ethics Committee and stored under the 
Human Tissue Authority licence.  
Tissue collection  
After fixation in 10% buffered formalin, brains were examined by a neuropathologist in accordance 
with QSBB protocol.  Seven μm thick paraffin sections were cut and de-paraffinized, followed by pre-
treatment with formic acid and pressure-cooking in citrate buffer at pH 6.0 and stained according to 
previously published methods.21  Nonspecific binding was blocked using 10% non-fat milk in 
phosphate-buffered saline.  Sections were incubated with antibodies recognizing Aβ, residues 17–26 
(Biosource Int, 1:4,000), α-synuclein (Novocastra, 1:75) or tau (AT8, Autogen Bioclear, 1:600). The 
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secondary antibody (Dako, 1:200) was then applied, followed by incubation with ABC (Dako) and 
colour development by di-aminobenzidine/H2O2. 
Quantification of pathology 
The frequency of neocortical Aβ-positive plaques (mature and diffuse) was assessed using Aβ 
immunohistochemistry (performed by T.L., Y.C. and T.R., blinded to clinical data) using a previously 
described protocol.7, 22  Using the approach recommended by CERAD, the severity of the cortical 
pathology for each plaque type was determined in a semi-quantitative manner as absent (grade 0), 
sparse (1), moderate (2) or frequent (3) for the following regions: frontal, temporal, occipital and 
parietal cortices; and entorhinal cortex.7  Scores for both mature (Plaquesum, range 0-15) and diffuse 
(Diffusesum, range 0-15) plaques were calculated, in addition to total Aβ plaque score 
(Plaquesum+Diffusesum, range 0-30).  α-synuclein pathology was assessed using a semi-quantitative 
grading system23 and Braak LB pathology stage was given for each case based on the distribution of 
LB.24 
A previously described and validated quantitative method was also used for determining the Aβ 
cortical load and LB counts.7, 8  As we have previously found a good correlation between the cingulate 
and entorhinal LB densities and total cortical LB densities (Spearman’s r = 0.985), and between 
temporal and parietal Aβ scores and total cortical Aβ scores (Spearman’s r = 0.975),7 using image 
analysis LB densities and Aβ load were also determined in these anatomical areas.  Regions of interest 
were outlined and the surface area of each section measured using the NIH Image J software 
(available at http://rsb.info.nih.gov/ij/applets.html).  In the selected areas all LBs were systematically 
counted and LB counts, adjusted to surface area, were expressed as LBs/mm2, with Aβ load density 
expressed/ mm2.  Intra- and inter-rater repeatability studies revealed that 95% of measurements fell 
within two standard deviations of the mean difference, with a correlation coefficient of 0.996. 
Cerebral amyloid angiopathy (CAA) was quantified based on a 4-tier grading system as described 
elsewhere7 in the same cortical and subcortical regions.  Using Aβ immunohistochemistry, the 
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presence or absence of Aβ-positive plaques was also measured in different brain regions and a Thal 
phase allocated to each case.25 
Neurofibrillary tangle pathology was determined using Braak staging26 and apolipoprotein E (APOE) 
genotype was determined for 24 Apo+ and 34 Apo- cases using previously described methods.7 
Statistics 
Subjects were classified by whether they had received apomorphine in life (Apo+) or not (Apo-) and 
cognitive status at the time of death (normal, CN, or impaired, CI), thus yielding four groups: 
Apo+CN, Apo-CN, Apo+CI and Apo-CI.  Data were analysed as Apo+CN vs. Apo-CN and Apo+CI 
vs. Apo-CI groups.  Statistical analyses were performed using SPSS 21.0 (SPSS, Chicago, IL). Means 
were compared using unpaired t-tests or Mann-Whitney tests, depending upon data distribution.  
Pearson Chi-Squared or Fisher’s exact tests were used to analyze categorical data.  One-tailed tests 
were used for the comparisons of Aβ deposition between groups only as our hypothesis was that Aβ 
load would be significantly less in the Apo+ cases.  Spearman’s rank correlation coefficients (two-
tailed) were calculated to assess bivariate associations between Aβ scores and apomorphine dose.  
Due to non-Normality in the Aβ plaque scores, statistical package R (version 2.15.3) was used to find 
a suitable model.  A negative binomial model in SPSS allowed comparison between groups whilst 
controlling for covariates.  As this was an exploratory study, a priori correction for multiple 
comparisons was not made; if a parameter was significant, even if by chance, we felt it merited further 
analysis.27  
Results 
Of the 43 Apo+ and 38 Apo- cases identified, eight and two, respectively, were excluded due to 
incomplete medical records or inadequate brain tissue samples.  The Apo+ group comprised seven 
subjects who used a pen (i.e. bolus) only as method of drug delivery, 15 who used continuous 
subcutaneous infusion and 13 who used both.  Nineteen of the Apo+ group (54.3%) and 17 of the 
Apo- group (47.2%) were classified as cognitively normal.  Groups were well matched for age at 
disease onset, disease duration, age at death and APOE4 genotype, in addition to other coexisting 
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(non-Aβ) diagnostic pathologies (table 1 and 2).  Cumulative levodopa dose and duration of other 
dopaminergic agents were similar across the groups, with the exception of significantly longer 
duration of selegiline use in the Apo-CI compared to Apo+CI group (mean 8.3 versus 4.4 years, 
p=0.044, Mann Whitney 2-sided test).  Male cases had significantly lower Aβ scores than females 
(median Plaquesum+Diffusesum scores 1.00 vs. 9.50, p=0.018 and Aβ load total 0.34 vs. 1.39, p=0.049, 
Mann-Whitney 2-sided test), although gender was not significantly different across the groups.    
Within the non-demented subjects, there was significantly reduced Aβ accumulation in Apo+ cases, 
with Diffusesum scores and Plaquesum+Diffusesum scores lower in the Apo+CN compared to Apo-CN 
group (table 2).  Total cortical LB density, however, was greater in the Apo-CN group, largely driven 
by a greater cingulate α-synuclein burden.  Of note, those previously exposed to apomorphine also 
had greater exposure to anticholinergic drugs, although no difference was observed in proportions of 
subjects who had taken anticholinergics for over 2 years (X2=1.69, p=0.311, Pearson Chi-Squared 
test).  No significant differences were noted within the cognitively impaired groups. 
APOE4 genotype is a risk factor for AD, dementia with Lewy bodies (DLB) and possibly also for 
PDD.28  Data were unavailable for APOE status in 13 participants (largely from the Apo+ group), so 
analyses were repeated only in cases where APOE status was available (supplementary table 1).  The 
groups remained well matched for general characteristics including age at death, disease duration and 
gender.  Significant differences persisted between the Apo+CN and Apo-CN group with respect to 
Diffusesum scores (median 0.00 vs. 3.00, respectively, p=0.046, Mann-Whitney 1-sided test) and 
Plaquesum+Diffusesum scores (0.00 vs. 3.00, p=0.029).  Interestingly, no differences were seen in total 
cortical LB density within the cognitively normal subgroups (median score Apo+CN 0.34 vs. 2.48 
Apo-CN, p= 0.179, Mann-Whitney 2-sided test). 
Within the whole Apo+ group, early dose of apomorphine used tended to be greater in those who 
were cognitively normal compared to cognitively impaired at death but did not reach statistical 
significance (median dose 44 vs. 11 mg, p=0.093, Mann-Whitney 2-sided test).  No significant 
differences were seen in one year dose, maximum dose, cumulative dose and duration of apomorphine 
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in those who were cognitively normal.  No difference in amyloid burden was seen in those using pen 
versus infusion delivery method, which is likely to be due to the small numbers within each group 
(data not shown).  In the Apo+CN group only, a significant negative correlation was seen between 
maximum apomorphine dose received and Plaquesum+Diffusesum score (r= -0.474, p=0.047, 
Spearman’s rho, Figure 1A).  Correlation between both maximum and early dose of apomorphine and 
Diffusesum score did not reach significance (r= -0.450, p=0.070 and r= -0.465, p=0.052, respectively, 
Spearman’s rho, Figure 1B and 1C).  The analyses were repeated after removal of the obvious outlier 
(a case receiving a maximum dose of apomorphine 400mg).  There was a significant association 
between early apomorphine dose and Diffusesum score (r= -0.504, p=0.046), with no significant 
correlation between maximum dose of apomorphine and Diffusesum score or Plaquesum+Diffusesum 
score (r= -0.431, p=0.084 and r= -0.444, p=0.076, respectively, Spearman’s rho, Figure 1D and 1E). 
To inform our selection of covariates that may predict Aβ in an explanatory model, we explored the 
association between Aβ score and gender, anticholinergic use, APOE status, age at disease onset, age 
at death, disease duration and cumulative levodopa dose (table 3).  Of these, only gender, APOE 
positivity and age at death were significantly associated.  These covariates were therefore entered into 
a negative binomial model with Plaquesum+Diffusesum score of the CN group as the dependent and 
early/maximum/one year/cumulative apomorphine dose; age at death; APOE positivity; and gender as 
independent variables.  Early and maximum dose were stable significant predictors of 
Plaquesum+Diffusesum score, with greater dose predicting reduced Aβ. The other dose calculations were 
not significant (table 3). 
Discussion 
This is the first clinicopathological study to investigate the relationship between amyloid burden in 
PD subjects who had received apomorphine ante-mortem, following reports of putative disease-
modifying effects in AD murine models.16  It is possible that apomorphine treatment may have a 
modifying effect on Aβ peptide deposition in non-demented PD cases, with our results demonstrating 
decreased diffuse and total plaque load in the Apo+ compared to Apo- group, reduced Aβ 
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accumulation in subjects who had received greater earlier and maximum apomorphine doses and an 
inverse association between maximum drug dose and Aβ peptide deposition.   
Mechanisms by which apomorphine may reduce Aβ accumulation include antioxidative prevention of 
apoptosis and synaptic injury, and greater degradation of intracellular Aβ, the latter potentially by 
upregulation of the proteasome system.16  In vitro work indicating that apomorphine inhibits Aβ fibril 
formation and stabilizes Aβ oligomeric species via hydroxyl groups on the D-ring of apomorphine 
and related compounds adds further support to a mechanistic basis for the observed benefits.15  Aβ42, 
containing 42 amino-acid residues, is a major constituent of mature amyloid plaques, and is highly 
prone to oligomerization and aggregation into fibrils.29-31  Conversely, Aβ40 is not found within 
diffuse plaques, which are not fibrillar and contain almost exclusively Aβ42 proteins; these may 
represent precursors of mature, neuritic plaques.31  Aβ42 is the more toxic of the species,29 and hence 
we speculate that the positive findings in our study that relate to diffuse plaque and total plaque load 
may be attributable to apomorphine-induced inhibition of Aβ42 to a greater degree than Aβ40.  This 
is substantiated by the observation that specifically it is diffuse plaque load which correlates with α-
synuclein pathology.7 
The finding of lower Aβ burden in the Apo+CN compared to Apo-CN group is strengthened by the 
fact that the former cases had greater anticholinergic exposure, which has been associated with 
increased Aβ plaque densities.19  However, this could also be explained by inadvertent sampling bias.  
Postural instability gait difficulty (PIGD) phenotype is a recognised risk factor for the development of 
PDD1, 32, 33 and has been associated with greater Aβ deposition than in tremor dominant subtypes,34, 35  
hence confounding-by-indication is a possibility.  Anticholinergic drugs were previously used to treat 
tremor and hence anticholinergic use in this study may reflect a proxy for motor phenotype; 
unfortunately the retrospective nature of this study meant that we were unable to account for motor 
heterogeneity.   
Within the Apo+CN group, total α-synuclein load was smaller than in the Apo-CN group, which is of 
significance as cortical Aβ deposition and LB load demonstrate a close association in Lewy body 
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diseases6, 7, 11 and may have contributed to the greater amyloid plaque burden in the Apo-CN cases.  
Moreover, recent studies have suggested that cortical LB pathology may be the principal pathological 
substrate of dementia in PD.9, 10   No differences were seen in α-synuclein load however, when 
analysis was limited to those cases where APOE status was available (supplementary table 1); 
significantly reduced Aβ deposition remained between the cognitively normal and impaired groups, 
thus strengthening our findings.  One study has previously demonstrated an association between tau 
pathology and cerebrovascular disease, with greater cerebrovascular lesion burden in PDD cases 
compared to age-matched controls.36  Others, however, have shown that cerebrovascular burden 
occurs in only a minority3, 9, 37 and is not a significant predictor of cognitive impairment.10  We believe 
that cerebrovascular disease is therefore unlikely to contribute to dementia in PD in a majority of 
patients.38 
In contrast to AD mouse models,16 we did not find differences in tau pathology between those who 
had and had not received apomorphine, which may represent differing underlying disease processes.  
It is interesting that differences were only seen within the cognitively normal group and not in those 
with dementia at the time of death.  Indeed, although significance was not reached, those in the 
Apo+CI group tended to have higher Aβ plaque densities than Apo-CI cases (table 2); we hypothesize 
that when apomorphine was stopped in the cognitively impaired group there may have been 
acceleration of Aβ deposition, or that the doses used in this population were insufficient to inhibit Aβ 
fibril formation.15  We note, however, that overall there were no differences in median doses of 
apomorphine between the groups, although those who were cognitively normal tended to have a 
higher early dose.  It is noteworthy that murine models used 5 to 10mg/kg of apomorphine per week 
(corresponding to 0.4-0.8mg/kg in humans)16 and whilst not reaching significance, the Apo+CN group 
in our study tended towards greater early, one year and maximum doses of apomorphine.  
Additionally, in vitro work has indicated that if apomorphine was added to cell culture after the 
neurotoxic insult, the antioxidant effect of the drug was significantly lessened;39 hence we speculate 
that apomorphine may have been commenced in the Apo+CI after the deposition of toxic Aβ and/or 
LB species and thus too late to observe a clinical effect.   
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Although this study has yielded some promising results, the data are exploratory and clearly require 
confirmation in larger cohorts and in vivo.  We acknowledge that one-tailed statistics, used due to the 
hypothesis-driven study, without correction for multiple hypotheses, could possibly render the 
associations observed as due to chance.  However, the fact that greater apomorphine doses remained a 
significant predictor of Aβ load in a model after adjusting for other covariates adds consistency and 
strength to our argument, as do the two-tailed Spearman’s correlations.  The study design at present 
cannot answer whether apomorphine prevents cognitive impairment, and would necessitate a 
prospective in vivo study.  The retrospective nature of our study mean that there are limitations as 
regards the cognitive state of individuals at time of death.  Furthermore, it is possible that there was an 
implicit bias in the decision not to use apomorphine in the Apo-CN group in subjects with subtle early 
signs of cognitive impairment that was not identified on case note review.  However, the groups were 
well matched for use of oral dopamine agonists and amantadine, which in clinical practice are more 
likely to be avoided in the face of cognitive decline.  Other limitations include ascertaining clinical 
information retrospectively, missing APOE genotype data and lack of precision in determining 
apomorphine cumulative dosages.  Whilst cumulative lifetime levodopa dose calculation is well 
established,20 apomorphine cumulative doses are more difficult to estimate and hence may have 
contributed to the lack of effect demonstrated in our work.  In conclusion, we postulate that 
apomorphine may represent a novel therapeutic agent to reduce the burden of cognitive impairment in 
PD.  
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